Evaluation of uveitis activity in Behcet's disease patients using BOS24
https://doi.org/10.21516/2072-0076-2017-10-4-30-37
Abstract
Purpose: to estimate the change of uveitis activity using Behcet’s disease ocular attack score 24 (BOS24) during anti-inflammatory and immunosuppressive therapy of Behcet's disease (BD) patients. Material and methods. 144 out of 205 patients (70.2 %) with confirmed BD diagnosis (according to the criteria set out in ISGBD, 1990) had ocular lesions, 83 of 144 (57.6 %) had acute uveitis, 145 eyes displayed active inflammation. Uveitis activity was estimated in dynamics using BOS24 score, which consisted of 6 parameters with the maximum level of 24 points. Results. The initial average BOS24 score for 145 eyes with active uveitis was 7.38 ± 0.71 points. The most pronounced inflammatory changes were revealed in posterior pole areas - mostly in retina periphery, less frequently in the area of fovea and the optic disc. All patients with uveitis exacerbation received systemic therapy including glucocorticoids, cyclosporine and/or azathioprine. After 9.43 ± 2.47 months of therapy, the average BOS24 score dropped significantly (р < 0.001) to 1.86 ± 0.48. The most notable positive changes were revealed in the anterior chamber (р < 0.001), the vitreous (р = 0.002) and in retinal periphery (р < 0.001). Conclusion. BOS24 is a reliable tool allowing a quantitative assessment of uveitis activity in BD patients and its change after anti-inflammatory and immunosuppressive therapy. For citations: Neroev V.V., Davydova G.A., Katargina L.A., Lisitsyna T.A., Khatagova Z.R., Alekberova Z.S. Evaluation of uveitis activity in Behcet's disease patients using BOS24. Russian ophthalmological journal. 2017; 10 (4): 30-7. doi: 10.21516/2072-0076-2017-10-4-30-37 (In Russian).
About the Authors
V. V. Neroev
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
G. A. Davydova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
L. A. Katargina
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
T. A. Lisitsyna
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Z. S. Alekberova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Z. R. Khatagova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
References
1. Алекберова З.С. Болезнь Бехчета. Москва: РАМН и ГУ ИР РАМН; 2007.
2. Nussenblatt R.B.Uveitis in Behçet's disease.Int. Rev. Immunol. 1997; 14(1): 67-79. Review. doi:10.3109/08830189709116845
3. Tugal-Tuktun I., Onal S., Altan-Yaycioglu R. Uveitis in Behcet’s disease: an analysis of 880 patients. Am J Ophthalmol. 2004; 138: 373-80.doi: 10.1016/j.ajo.2004.03.022
4. Ohguro N., Sonoda K.H., Takeuchi M., Matsumura M., Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432-5. doi:10.1007/s10384-012-0158-z
5. Kaburaki T., Namba K., Sonoda K.H., et al. Ocular BehçetDiseaseResearch Group of Japan. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58 (2Mar): 120-30.doi:10.1007/s10384-013-0294-0
6. Hatemi G., Silman A., Bang D., et al. Management of Behçet’s disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behcet’s disease. Ann Rheum Dis. 2008; 67:1656-62. doi: 10.1136/ard.2008.087957.
7. Ohno S., Nakamura S., Hori S., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
8. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., Markomichelakis N.N. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001; 358:295-6. http://dx.doi.org/10.1016/s0140-6736(01)05497-6
9. Niccoli L., Nannini C., Benucci M., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-4. http://dx.doi.org/10.1093/rheumatology/kem101
10. Hazirolan D., Stübiger N., Pleyer U. Light on the Horizont: biologicals in Behçet uveitis. ActaOphthalmol. 2013: 91: 297-306 http://dx.doi.org/10.1111/j.1755-3768.2011.02348.x
11. Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 2007: 21, 824-825 http://dx.doi.org/10.1038/sj.eye.6702352
12. Benitah N.R., Sobrin L., Papaliodis G.N.The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. SeminOphthalmol. 2011;26(4-5Jul-Sep;): 295-303. doi:10.3109/08820538.2011.588665
13. Calvo Catalá J., Campos Fernandez C., Rueda Cid A., et al. Efficacy of adalimumab in Behçet’s disease. Description of 6 cases. ReumatolClin. 2011;7(4):258-61. http://dx.doi.org/10.1016/s2173-5743(11)70056-9
14. BhaktaB.B., Brennan P., James T.E., et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38: 728-33. http://dx.doi.org/10.1093/rheumatology/38.8.728
15. LawtonG., Bhakta B.B., Chamberlain M.A., Tennant A. The Behçet’s disease activity index. Rheumatology (Oxford). 2004; 43: 73-8. http://dx.doi.org/10.1093/rheumatology/keg453
16. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078-80. http://dx.doi.org/10.1016/0140-736(90)92643-V
17. Zoubouli sCh., Vaiopoulos G., Macromichelakis N., et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behçet's disease in Greece. ClinExp Rheum. 2003; 21 (suppl.30):19-26.
18. Jabs D.A, Nussenblatt R.B, Rosenbaum J.T. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140:509-16. http://dx.doi.org/10.1016/j.ajo.2005.03.057
19. Nussenblatt R.B, Palestine A.G, Chan C.C, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985; 92:467-71. http://dx.doi.org/10.1016/s0161-6420(85)34001-0
20. OkadaA.A., Goto H., Ohno S., Mochizuki M. Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592-8.doi: 10.1001/archophthalmol.2011.2698.
Review
For citations:
Neroev V.V., Davydova G.A., Katargina L.A., Lisitsyna T.A., Alekberova Z.S., Khatagova Z.R. Evaluation of uveitis activity in Behcet's disease patients using BOS24. Russian Ophthalmological Journal. 2017;10(4):30-37. https://doi.org/10.21516/2072-0076-2017-10-4-30-37
Views:
586
Email this article 